27:
214:
172:
is sometimes used when the initial chemotherapy does not lead to improvement. An alternative would be administering a second chemotherapy if the disease progresses. A significant number of patients do not survive long enough for a second treatment if their disease progresses. When maintenance therapy
128:
The full name of the trial is "A Phase 3, Double-Blind, Placebo-Controlled Study of
Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment with Pemetrexed + Cisplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer". Its common name
291:
Paz-Ares, L.; De
Marinis, F.; Dediu, M.; Thomas, M.; Pujol, J. L.; Bidoli, P.; Molinier, O.; Sahoo, T. P.; Laack, E.; Reck, M.; Corral, J. S.; Melemed, S.; John, W.; Chouaki, N.; Zimmermann, A. H.; Visseren-Grul, C.; Gridelli, C. (2012). "Maintenance therapy with pemetrexed plus best supportive care
221:
The study intended to enroll 939 people. The study started in
November 2008 and was estimated to be completed in September 2013. The study was conducted at locations in Australia, Belgium, Finland, France, Germany, Greece, India, Italy, the Netherlands, Poland, Portugal, Romania, Spain, Turkey, and
201:
PARAMOUNT found that maintenance therapy with pemetrexed for patients with advanced non-squamous NSCLC was an effective and well tolerated treatment option in those patients who had not had progress after initial therapy with pemetrexed plus cisplatin. The average life of all participants receiving
342:"Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer"
188:
or as a maintenance drug when not part of the initial therapy. The PARAMOUNT study was designed to measure the extent of the efficacy when a patient received pemetrexed maintenance therapy after cisplatin/pemetrexed initial therapy. The study would measure progression-free survival of patients and
202:
the experimental treatment increased more than 13 months as compared to the control group. The results of this trial should not be generalized beyond the scope of the research and the trial design must be considered to interpret these results.
292:
versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial".
111:
for patients with advanced non-squamous NSCLC was an effective and well-tolerated treatment option in those patients who had not had progress after initial therapy with pemetrexed plus
240:
634:
530:
Rothschild, S. I.; Gautschi, O. (2011). "Maintenance therapy for patients with advanced non-small cell lung cancer: Who to treat and how to treat?".
104:
and was conducted in several
European countries and Canada. It was registered in November 2008 and was projected to end in September 2013.
189:
survival irrespective of whether the cancer had progressed. An additional study goal would be to check the extent to which measurement of
391:
Gridelli, C.; Di Maio, M. (2010). "The role of pemetrexed as maintenance treatment in advanced NSCLC: A Phase III randomized trial".
226:
205:
The result of this trial did not change the fact that the concept of maintenance therapy remains controversial and complicated.
624:
585:
236:
165:
150:
97:
26:
193:- the naturally produced enzyme on which pemetrexed acts - could predict the efficacy of pemetrexed in these cases.
233:
260:
248:
268:
184:, had been an effective therapy for patients with NSCLC when used either as an initial chemotherapy with
101:
48:
629:
256:
252:
190:
576:"A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer"
169:
580:
547:
416:
154:
130:
495:
Eaton, K. D.; Martins, R. G. (2010). "Maintenance chemotherapy in non-small cell lung cancer".
512:
451:
408:
373:
309:
264:
575:
539:
504:
443:
400:
363:
353:
301:
255:
and non-small-cell lung carcinoma or have had another form of cancer other than superficial
142:
470:
368:
341:
340:
Paz-Ares, L. G.; Altug, S.; Vaury, A.; Jaime, J.; Russo, F.; Visseren-Grul, C. (2010).
230:
93:
609:
305:
618:
447:
173:
is used it may or may not consist of a different drug than the initial chemotherapy.
551:
213:
420:
543:
404:
181:
177:
146:
108:
267:
of the cervix within the last 5 years. Patients with a history of low-grade (
508:
358:
185:
158:
112:
516:
455:
412:
377:
313:
271:
score equal to or less than 6) localized prostate cancer are eligible.
244:
212:
286:
284:
141:
The PARAMOUNT trial investigated whether treatment with a
16:
Clinical trial studying non-small-cell lung carcinoma
569:
567:
565:
563:
561:
497:
Journal of the
National Comprehensive Cancer Network
31:
text from a representative informed consent document
434:Baldwin, C. M.; Perry, C. M. (2009). "Pemetrexed".
78:
70:
62:
54:
44:
36:
243:guidelines or disease which can be examined by a
239:and have at least one measurable tumor lesion by
335:
333:
331:
329:
327:
325:
323:
107:PARAMOUNT found that maintenance therapy with
8:
532:Memo - Magazine of European Medical Oncology
241:Response Evaluation Criteria in Solid Tumors
19:
229:, participants must in the trial must have
367:
357:
471:"ASCO: Alimta Extends Survival in NSCLC"
574:Eli Lilly and Company (April 3, 2013).
280:
18:
176:Studies prior to PARAMOUNT had shown
7:
247:, but must not have non-superficial
100:(NSCLC). The trial was sponsored by
14:
635:Clinical trials related to cancer
469:Bankhead, Charles (8 June 2012).
393:Expert Opinion on Pharmacotherapy
153:and improve survival rates after
448:10.2165/11202640-000000000-00000
227:inclusion and exclusion criteria
25:
1:
586:National Institutes of Health
306:10.1016/S1470-2045(12)70063-3
237:non-small-cell lung carcinoma
166:non-small cell lung carcinoma
151:non-small-cell lung carcinoma
98:non-small-cell lung carcinoma
149:would inhibit the growth of
164:For patients with advanced
133:identifier is NCT00789373.
651:
544:10.1007/s12254-011-0242-y
405:10.1517/14656560903485672
217:Illustration of the lungs
24:
610:clinicaltrials.gov entry
509:10.6004/jnccn.2010.0058
359:10.1186/1471-2407-10-85
261:squamous-cell carcinoma
249:squamous-cell carcinoma
269:Gleason Grading System
218:
55:number of participants
40:PARAMOUNT, NCT00789373
625:Eli Lilly and Company
251:or a mixture of both
216:
157:with pemetrexed plus
102:Eli Lilly and Company
49:Eli Lilly and Company
257:basal-cell carcinoma
253:small-cell carcinoma
222:the United Kingdom.
191:thymidylate synthase
294:The Lancet Oncology
170:maintenance therapy
21:
581:clinicaltrials.gov
219:
209:Study participants
155:first-line therapy
131:ClinicalTrials.gov
129:is PARAMOUNT. Its
79:primary completion
442:(16): 2279–2302.
265:carcinoma in situ
86:
85:
642:
597:
596:
594:
592:
571:
556:
555:
527:
521:
520:
492:
486:
485:
483:
481:
466:
460:
459:
431:
425:
424:
388:
382:
381:
371:
361:
337:
318:
317:
288:
259:and superficial
231:stage IIIB or IV
143:maintenance dose
29:
22:
650:
649:
645:
644:
643:
641:
640:
639:
615:
614:
606:
601:
600:
590:
588:
573:
572:
559:
529:
528:
524:
494:
493:
489:
479:
477:
468:
467:
463:
433:
432:
428:
390:
389:
385:
339:
338:
321:
290:
289:
282:
277:
211:
199:
139:
126:
121:
90:PARAMOUNT trial
32:
20:PARAMOUNT trial
17:
12:
11:
5:
648:
646:
638:
637:
632:
627:
617:
616:
613:
612:
605:
604:External links
602:
599:
598:
557:
522:
503:(7): 815–821.
487:
461:
426:
399:(2): 321–324.
383:
319:
300:(3): 247–255.
279:
278:
276:
273:
210:
207:
198:
195:
138:
135:
125:
122:
120:
117:
94:clinical trial
84:
83:
80:
76:
75:
74:September 2013
72:
68:
67:
64:
60:
59:
56:
52:
51:
46:
42:
41:
38:
34:
33:
30:
15:
13:
10:
9:
6:
4:
3:
2:
647:
636:
633:
631:
628:
626:
623:
622:
620:
611:
608:
607:
603:
587:
583:
582:
577:
570:
568:
566:
564:
562:
558:
553:
549:
545:
541:
537:
533:
526:
523:
518:
514:
510:
506:
502:
498:
491:
488:
476:
475:MedPage Today
472:
465:
462:
457:
453:
449:
445:
441:
437:
430:
427:
422:
418:
414:
410:
406:
402:
398:
394:
387:
384:
379:
375:
370:
365:
360:
355:
351:
347:
343:
336:
334:
332:
330:
328:
326:
324:
320:
315:
311:
307:
303:
299:
295:
287:
285:
281:
274:
272:
270:
266:
262:
258:
254:
250:
246:
242:
238:
235:
232:
228:
223:
215:
208:
206:
203:
196:
194:
192:
187:
183:
179:
174:
171:
167:
162:
160:
156:
152:
148:
144:
136:
134:
132:
123:
118:
116:
114:
110:
105:
103:
99:
95:
91:
81:
77:
73:
69:
66:November 2008
65:
61:
57:
53:
50:
47:
43:
39:
35:
28:
23:
591:14 September
589:. Retrieved
579:
535:
531:
525:
500:
496:
490:
480:16 September
478:. Retrieved
474:
464:
439:
435:
429:
396:
392:
386:
349:
345:
297:
293:
225:Among other
224:
220:
204:
200:
175:
163:
140:
127:
119:Study design
106:
89:
87:
630:Lung cancer
234:nonsquamous
37:other names
619:Categories
346:BMC Cancer
275:References
182:antifolate
178:pemetrexed
147:pemetrexed
109:pemetrexed
538:: 19–22.
186:cisplatin
168:(NSCLC),
159:cisplatin
113:cisplatin
96:studying
82:June 2010
552:71344182
517:20679540
456:19852529
413:20053140
378:20211022
314:22341744
421:6657623
369:2847958
245:CT scan
197:Outcome
137:Purpose
45:sponsor
550:
515:
454:
419:
411:
376:
366:
352:: 85.
312:
548:S2CID
436:Drugs
417:S2CID
263:, or
180:, an
92:is a
63:start
593:2013
513:PMID
482:2013
452:PMID
409:PMID
374:PMID
310:PMID
124:Name
88:The
540:doi
505:doi
444:doi
401:doi
364:PMC
354:doi
302:doi
145:of
71:end
58:939
621::
584:.
578:.
560:^
546:.
534:.
511:.
499:.
473:.
450:.
440:69
438:.
415:.
407:.
397:11
395:.
372:.
362:.
350:10
348:.
344:.
322:^
308:.
298:13
296:.
283:^
161:.
115:.
595:.
554:.
542::
536:4
519:.
507::
501:8
484:.
458:.
446::
423:.
403::
380:.
356::
316:.
304::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
